Cathie Wood drops $1.3 million on healthcare stock

Cathie Wood has seldom shied distant from letting everyone cognize wherever she believes the adjacent question of market-changing businesses volition travel from.

Though ARK Invest’s regular trades spark a ton of excitement, its latest buying successful CRISPR Therapeutics (CRSP) is acold from being a abrupt shift.

The speculative healthcare banal specializes successful cistron editing, a exertion that’s a cardinal constituent of Wood’s imaginativeness for transformational innovation.

Think of cistron editing the mode investors thought of the net backmost successful the 90s.

Early and messy, but with tremendous imaginable to softly rewire full industries. For Wood, genomics is fundamentally a toolbox that tin efficaciously alteration however diseases are treated, overmuch similar bundle has changed however businesses operate.

As Cathie Wood has said,

Hence, crossed Cathie Wood’s ARK ETFs combined, CRISPR makes up roughly 3.81% of assets, indicating her latest buying spree is simply a dependable doubling down connected a semipermanent vision.

CRISPR Therapeutics' banal headlined Wood’s holiday-week trading.

Fund manager buys and sells

• Cathie Wood sells $40 cardinal of megacap tech stock

• Jim Cramer issues blunt 5-word verdict connected Nvidia stock

• Longtime money manager’s 2-word stock-market prediction for 2026

• Manager of $24 cardinal golden ETF sets 2030 terms target

On Friday, December 26, ARK acquired 23,170 shares of CRISPR, spending implicit $1.3 million.

The purchases were divided crossed ETFs, with 19,965 shares added to ARKK and 3,205 shares added to ARKG.

That determination wasn’t isolated, though.

In the aforesaid week, ARK bought 10,353 CRISPR shares connected Wednesday, worthy astir $584,530, followed by an adjacent bigger stake connected Tuesday, erstwhile it snapped up 43,333 shares for astir $2.51 million.

In total, ARK loaded up connected implicit 76,800 shares of CRISPR successful conscionable 3 trading days.

For much color, CRISPR exertion fundamentally works similar a robust connection processor for DNA. It uses a usher RNA to find a circumstantial familial “sentence,” past an enzyme cuts it, allowing the compartment to repair oregon rewrite it.

For diseases that are caused by a circumstantial faulty gene, that could mean fixing the occupation astatine its halfway alternatively of conscionable managing symptoms.

Other notable ARK trades that week:

• Tuesday: Bought 333,370 shares of Pacific Biosciences for $606,733

• Wednesday: Bought 101,637 shares of WeRide for $901,520

• Wednesday: Sold 101 shares of Ibotta for $2,173

CRISPR Therapeutics occupies a presumption that galore see an uncomfortable mediate crushed for investors.

Related: Popular expert sets bold 2026 terms people connected Nvidia stock

The institution isn’t strictly pre-revenue, but inactive early-commercial successful the mode investors usually mean.